Evidence map›Paper›PMID 36159875›Full record

ArticleFrontiers in immunology2022

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer.

David G Coffey, Yuexin Xu, Andrea M H Towlerton, Marcin Kowanetz, Priti Hegde, Martine Darwish, Mahesh Yadav, Craig Blanchette, Shannon M Ruppert, Sarah Bertino and 8 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

David G CoffeyDepartment of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Yuexin XuDepartment of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Andrea M H TowlertonDepartment of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Marcin KowanetzArriVent Biopharma, Newtown Square, PA, United States.
Priti HegdeFoundation Medicine, Cambridge, MA, United States.
Martine DarwishGenentech, San Francisco, CA, United States.
Mahesh YadavGenentech, San Francisco, CA, United States.
Craig BlanchetteGenentech, San Francisco, CA, United States.
Shannon M RuppertGenentech, San Francisco, CA, United States.
Sarah BertinoTScan Therapeutics, Waltham, MA, United States.
Qikai XuTScan Therapeutics, Waltham, MA, United States.
Andrew FerrettiTScan Therapeutics, Waltham, MA, United States.
Adam WeinheimerTScan Therapeutics, Waltham, MA, United States.
Matthew HellmannAstraZeneca, Wilmington, DE, United States.
Angel QinDepartment of Medicine, University of Michigan, Ann Arbor, MI, United States.
Dafydd ThomasDepartment of Pathology, University of Michigan, Ann Arbor, MI, United States.
Edus H WarrenDepartment of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Nithya RamnathDepartment of Medicine, University of Michigan, Ann Arbor, MI, United States.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
NCI NIH HHS P30 CA015704NIH HHS S10 OD028685
6 · The paper itself

Abstract

Most patients with advanced non-small cell lung cancer (NSCLC) do not achieve a durable remission after treatment with immune checkpoint inhibitors. Here we report the clinical history of an exceptional responder to radiation and anti-program death-ligand 1 (PD-L1) monoclonal antibody, atezolizumab, for metastatic NSCLC who remains in a complete remission more than 8 years after treatment. Sequencing of the patient's T cell repertoire from a metastatic lesion and the blood before and after anti-PD-L1 treatment revealed oligoclonal T cell expansion. Characterization of the dominant T cell clone, which comprised 10% of all clones and increased 10-fold in the blood post-treatment, revealed an activated CD8

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedHLA-A2 AntigenHumansImmune Checkpoint InhibitorsT-LymphocytesAntibodies, Monoclonal, HumanizedatezolizumabHLA-A2 AntigenImmune Checkpoint Inhibitorscase reportimmunotherapylung neoplasmsprogrammed death-ligand 1t lymphocytes

Identifiers

PMID36159875
PMCPMC9500393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.